Publications

Search our bibliography using the filters on the right-hand side.

Displaying 351 through 400 of 408 publications.

Douillard JY, Cella D, Natale R, Lynch TL, Lee C, Carbone D, Kay A, Wolf M M, Heyes AE, Ward J. Clinically meaningful improvement in disease-related symptoms by 'gefitinib' (Iressa, ZD1839) in patients with advanced non-small cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival. Presented at the European Cancer Conference 12; September 2003; September 2003. Copenhagen, Denmark.

Rowland CR, Barrows SM, Brown MT. Effects of valdecoxib on functional impairment, quality of life and treatment satisfaction in migraine patients. Poster presented at the Annual Meeting of the International Headache Society; September 2003.

Njue AI, Prichard RK. Heterologous expression of glutamate-gated chloride channel subunits from cooperia oncophora. Poster presented at the 19th International Conference of the World Association for the Advancement of Veterinary Parasitology; August 2003.

LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun 1;9(6):2040-8.

Coombs JH, Abetz L, Keininger DL, Earle CC, Copley-Merriman K, Hsu M-A, Bury-Maynard DP. Development of the Cancer Chemotherapy Satisfaction Questionnaire (CCSQ): part I: item-generation and content validity testing. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:545.

Osoba D, Hsu M-A, Copley-Merriman K, Johnson FR, Hauber AB, Coombs J. Cancer patients' preferences for health-related quality of life (HRQOL) domains during treatment. Poster presented at the 2003 Annual Meeting of the American Society of Clinical Oncology; May 2003.

Cella D, Natale R, Lynch T T, Lee C, Carbone D, Douillard JY, Kay A, Wolf M, Heyes AE, Ward J. Disease-related symptoms in advanced nsclc as measured by the lung cancer subscale (LCS) of the fact-l questionnaire: clinically meaningful improvement with gefitinib (Iressa, ZD1839). Presented at the American Society of Clinical Oncology; May 2003. Chicago, IL.

Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm. 2003 May 1;9(3):223-31.

Clark M, Copley-Merriman K, Coombs JH, Von Pawel J, Koschel G, Pauer LR. Patient reported outcomes (symptoms, functioning, and quality of life [QOL]) in a randomized Phase II study of CI-994 plus carboplatin and paclitaxel (C/T) vs placebo (PBO) plus C/T in the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC). Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:687.

Trump DL, Wilding G, Miller K, Small E, Soulie P, Trachtenberg J, Raabe N, Heyes AE, Das-Gupta A. Pilot trials of ZD1839 ('Iressa'), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisolone or docetaxel/estramustine in patients with hormone-refractory prostate cancer. Presented at the American Urology Association; April 2003. Chicago, IL.

Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003 Feb 1;4(2):131-9.

McBurney C, Coombs J, Hsu M, Abetz L, Keininger D, Copley-Merriman K. An appraisal of treatment satisfaction and patient preference assessments in patients diagnosed with cancer. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; 2003. [abstract] Value Health. 5(3):201.

Duff SB, Mordin MM. Strategies for assessing health economic and quality-of-life outcomes in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2002 Dec;2(6):577-87.

Soni MK, Cella D, Masters GA, Burch SP, Heyes AE, Silberman C. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer. 2002 Nov;4(3):153-60.

Coombs J, McBurney C, Gondek K, Copley-Merriman C. Evidence of patient reported outcomes in labeling for oncology products: evaluation of United States and European labels. Mapi Quality of Life Newsletter. 2002 Oct;29:1-3.

Douillard JY, Skarin A, Baselga J, Natale R, Giaccone G, Maddox A, Heyes AE. Improvement in disease-related symptoms and quality of life (QOL) in patients treated with advanced non-small cell lung cancer (NSCLC) treated with zd1839 in ideal1 and ideal2. Poster presented at the European Society for Medical Oncology; October 2002. Nice, France.

Salerno DF, Copley-Merriman C, Taylor TN, Shinogle J, Schulz RM. A review of functional status measures for workers with upper extremity disorders. Occup Environ Med. 2002 Oct;59(10):664-70.

Njue AI, Prichard RK. Is tubulin linked to ivermectin resistance? Poster presented at the 10th International Congress of Parasitology; August 2002.

Njue AI, Prichard RK. Characterizing two glutamate receptor subunits from the cattle nematode Cooperia oncophora. Poster presented at the 47th Annual Meeting of the American Association of Veterinary Parasitologists; July 2002.

Copley-Merriman K, Pawel J, Shepard F, Kimmel K, Gulyas S, Eckert S. Randomized phase 2 study of the oral histone deacetylase inhibitor ci-994 plus gemcitabine vs. placebo plus gemcitabine in second-line nsclc: health-related quality of life results. Poster presented at the American Society of Clinical Oncology; May 2002. Orlando, FL.

Lewis B, Silberman C, Heyes AE. Side effects of chemotherapy among patients with ovarian cancer. Presented at the International Society for Pharmacoeconomics and Outcomes Research 7th Annual International Meeting; May 2002. Washington, DC.

Dennison CR, Leidy NK, Silberman C, Heyes AE. Interpretation of quality of life data from a clinician's point of view: getting to the clinically meaningful change. Presented at the Mayo Clinic Meeting: Assessing Clinical Significance for Quality of Live Measures in Oncology Research; April 2002. Rochester, MN.

Rieux C, Carney R, Lupi D, Dkhissi-Benyahya O, Jansen K, Chounlamountri N, Foster RG, Cooper HM. Analysis of immunohistochemical label of Fos protein in the suprachiasmatic nucleus: comparison of different methods of quantification. J Biol Rhythms. 2002 Apr;17(2):121-36. doi: 10.1177/074873002129002410

Leidy NK, Jonas D, Silberman C, Margolis MK, Heyes AE. What does it all mean? Using health-related quality of life data to interpret treatment outcomes. Presented at the Mayo Clinic Meeting: Assessing Clinical Significance for Quality of Live Measures in Oncology Research; April 2002. Rochester, MN.

Carney R, Dardis C, Cullen WK, Felipo V, Anwyl R, Rowan MJ. Early spatial memory deficit induced by 2,5-hexanedione in the rat. Toxicol Lett. 2002 Mar 10;128(1-3):107-15. doi: 10.1016/s0378-4274(01)00538-0

Shah S, Sesti AM, Copley-Merriman K, Clark M. Summary of quality of life labeling components in the package inserts. Poster presented at the DIA-QOL Meeting; March 2002.

Cella D, Eton DT, Faircloth DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar;55(3):285-95.

Menter A, Gottlieb A, Griffiths C, Mordin MM. Health-related quality of life impact of weekly intravenous or intramuscular alefacept in patients with psoriasis: results from two randomized, placebo-controlled phase III trials. Poster presented at the Annual Meeting of the American Academy of Dermatology; February 2002.

Santanello NC, Baker D, Cappelleri JC, Copley-Merriman K, DeMarinis R, Gagnon JP, Hsuan A, Jackson J, Mahmoud R, Miller D, Morgan M, Osterhaus J, Tilson H, Willke R. Regulatory issues for health-related quality of life—PhRMA Health Outcomes Committee Workshop, 1999. Value Health. 2002 Jan;5(1):14-25.

Leidy NK, Jonas D, Silberman C, Heyes AE. What role do symptoms play in health-related quality of life? Poster presented at the 8th Annual Conference of the International Society for Quality of Life Research; November 2001. Amsterdam, The Netherlands.

Jonas D, Leidy NK, Silberman C, Margolis MK, Heyes AE. Cognitive factors in symptom assessment: are we asking too much? Poster presented at the 8th Annual Conference of the International Society for Quality of Life Research; November 2001. Amsterdam, The Netherlands.

Sorensen SV, Chambers M, Heyes AE. An economic model for the pharmacological management of advanced non-small cell lung cancer in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; 2001. Cannes, France. [abstract] Value Health. 2001 Sep; 4(6):403.

Njue AI, Feng X-P, Prichard RK. Ivermectin resistance and the glutamate-gated chloride channels in the cattle nematode cooperia oncophora. Poster presented at the 18th International Conference of the World Association for the Advancement of Veterinary Parasitology; August 2001.

Buchner DA, Graboys TB, Johnson K, Mordin MM, Goodman L, Partsch DS, Goss TF. Development and validation of the ITG Health-Related Quality-of- Life Short-Form measure for use in patients with coronary artery disease. Integrated Therapeutics Group. Clin Cardiol. 2001 Aug;24(8):556-63.

Yang J, Bogerd HP, Wang PJ, Page DC, Cullen BR. Two closely related human nuclear export factors utilize entirely distinct export pathways. Mol Cell. 2001 Aug;8(2):397-406.

Shah S, Sesti AM, Chopra T, McLaughlin-Miley C, Copley-Merriman K. Quality of life terminology documented in package inserts. Mapi Quality of Life Newsletter. 2001 Jul;27:1-3.

Njue AI, Prichard RK. Ivermectin resistance in cooperia oncophora and beta-tubulin. Poster presented at the 46th Annual Meeting of the American Association of Veterinary Parasitologists; July 2001.

Anderson H, Espinosa E, Lofts F, Meehan M, Hutchinson G, Price N, Heyes AE. Evaluation of the Chemotherapy Patient Monitor: an interactive tool for facilitating communication between patients and oncologists during the cancer consultation. Eur J Cancer Care (Engl). 2001 Jun;10(2):115-23.

Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Wolf MK. What is a clinically meaningful change (CMC) on the functional assessment of cancer therapy - lung (FACT-L): analysis of ecog 5592 data. Poster presented at the 37th Annual Meeting of the American Society of Clinical Oncology; May 2001. San Francisco, CA.

Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Wolf MK. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy - Lung (FACT-L): analysis of ECOG 5592 data. Poster presented at the 7th Central European Lung Cancer Conference; June 2001. Prague, Czech Republic. [abstract] Lung Cancer. 2001 May; 32(Suppl 1):52.

Leidy NK, Jonas D, Margolis MK, Heyes AE, Jones K, Silberman C. On health-related quality of life, symptoms and the complementary nature of two patient-reported outcomes. Presented at the Drug Information Association Symposium of Contributed Papers on Quality of Life Evaluation; March 2001. Hilton Head, SC.

Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Bonomi P, Wolf MK. What is a clinically meaningful change (CMC) on the Functional Assessment of Cancer Therapy (lung) (FACT-L): analysis of ECOG 5592 data. Lung Cancer. 2001;373-6.

Yang J, Bogerd HP, Le S, Cullen BR. The human endogenous retrovirus K Rev response element coincides with a predicted RNA folding region. RNA. 2000 Nov;6:1551-64.

Bogerd HP, Wiegand HL, Yang J, Cullen BR. Mutational definition of functional domains within the Rev homolog encoded by human endogenous retrovirus K. J Virol. 2000 Oct;74(20):9353-61.

Njue AI, Prichard RK. Cloning a glutamate-gated chloride channel gene homologue from the cattle nematode cooperia oncophora. Poster presented at the 45th Annual Meeting of the American Association of Veterinary Parasitologists; July 2000.

Sesti A, Albright A, McLaughlin-Miley A, Copley-Merriman K. A methodology to measure productivity of health outcomes groups. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; May 2000.

Wang A, Graham L, Copley-Merriman K. Treatment satisfaction in outcomes research: an overview of study measures. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; May 2000.

Sculpher M, Palmer MK, Heyes AE. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics. 2000 Apr;17(4):361-70.

McGrath M. Issues in designing, selecting, and interpreting a quality of life instrument. Poster presented at the Outcomes Research & Design Conference; March 2000.

Caro JJ, Klittich WS, Raggio G, Kavanagh PL, O'Brien JA, Shomphe LA, Flegel KM, Copley-Merriman C, Sigler C. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther. 2000 Jan;22(1):116-27.